Kalvista Pharmaceuticals Stock Alpha and Beta Analysis
| KALV Stock | USD 9.33 0.01 0.11% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kalvista Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kalvista Pharmaceuticals over a specified time horizon. Remember, high Kalvista Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kalvista Pharmaceuticals' market risk premium analysis include:
Beta 1.79 | Alpha (0.57) | Risk 4.73 | Sharpe Ratio (0.09) | Expected Return (0.43) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kalvista |
Kalvista Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kalvista Pharmaceuticals market risk premium is the additional return an investor will receive from holding Kalvista Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kalvista Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kalvista Pharmaceuticals' performance over market.| α | -0.57 | β | 1.79 |
Kalvista Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kalvista Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Kalvista Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kalvista Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Kalvista Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kalvista Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kalvista Pharmaceuticals stock market price indicators, traders can identify Kalvista Pharmaceuticals position entry and exit signals to maximize returns.
Kalvista Pharmaceuticals Return and Market Media
The median price of Kalvista Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 11.41 with a coefficient of variation of 9.34. The daily time series for the period is distributed with a sample standard deviation of 1.06, arithmetic mean of 11.4, and mean deviation of 0.85. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 09/04/2024 |
2 | Disposition of 7352 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 12.1901 subject to Rule 16b-3 | 09/09/2024 |
3 | KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum | 09/26/2024 |
4 | KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema | 09/30/2024 |
5 | Acquisition by Unkart Edward W of 10000 shares of Kalvista Pharmaceuticals at 11.54 subject to Rule 16b-3 | 10/03/2024 |
6 | KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma Immunology | 10/18/2024 |
7 | Acquisition by Audhya Paul K. of 30613 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 10/28/2024 |
8 | KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of 5 Million | 11/04/2024 |
9 | Vanguard Group Incs Strategic Acquisition in KalVista Pharmaceuticals Inc | 11/05/2024 |
10 | Insight into TANG CAPITAL MANAGEMENT LLCs Strategic Acquisition of KalVista Pharmaceuticals ... | 11/15/2024 |
11 | Disposition of 8077 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.2566 subject to Rule 16b-3 | 11/18/2024 |
12 | Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16b-3 | 11/20/2024 |
About Kalvista Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kalvista or other stocks. Alpha measures the amount that position in Kalvista Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2020 | 2023 (projected) | Graham Number | 26.57 | 20.86 | Receivables Turnover | 1.22 | 1.4 |
Kalvista Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Kalvista Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kalvista Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kalvista Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kalvista Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 5th of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 5th of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Build Portfolio with Kalvista Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.